Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: AXL signaling in cancer: from molecular insights to targeted therapies

Fig. 1

Structure and activation mechanisms of the TYRO3, AXL, and MERTK (TAM) receptors. a The TAM receptors and ligands share closely related structures. The structure of growth arrest-specific protein 6 (GAS6) and vitamin K-dependent protein S (PROS1) comprises a γ-carboxyglutamic acid (GLA) domain, a loop region, four epidermal growth factor-like (EGF-like) repeats, and two C-terminal globular laminin G-like (LG) domains. TAM receptors consist of two immunoglobulin-like (Ig) domains, two fibronectin III (FNIII) repeat domains, and a kinase domain. GAS6 binds to all three receptors, while PROS1 binds to MERTK and TYRO3, but not to AXL. The decreasing width of the arrows indicates a reduction in receptor activation strength by the ligands, reflecting their relative affinities. b Ligand-Dependent Activation: Binding of GAS6 to AXL leads to receptor activation. Optimal activation requires PtdSer (phosphatidylserine) on the opposed cell membrane, which binds to the GLA domain of the ligand. c Ligand-Independent Activation: Various factors in the tumor microenvironment can activate AXL in a ligand-independent manner. d Homophilic Interaction: Activation can occur through interaction between AXL monomers on neighboring cells. e Heterophilic Activation: AXL can also be activated heterophilically with non-TAM receptors. Activation of AXL through these mechanisms results in autophosphorylation of intracellular tyrosine residues, initiating signaling pathways that promote tumor proliferation, invasion, migration, angiogenesis, drug resistance, and immune evasion

Back to article page